Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996437 · ClinicalTrials.gov registry record · Phase 2
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
A Phase 2 study, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT00996437 is a Phase 2 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 261 participants.
The verdict
NCT00996437, a Phase 2 study, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.
Interventions
- DRUG Saline
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996437
The ClinicalTrials.gov registry entry for NCT00996437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT00996437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996437 about?
NCT00996437 is a clinical study titled "Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)". This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.
What is the current status of trial NCT00996437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2010-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00996437?
The interventions under investigation include: Saline (DRUG), Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00996437?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.